Reviewing Interleukin 17– and Interleukin 23–targeting Therapies and Best Practices in Psoriatic Disease Management Feat. Clinical Practice Video Vignettes

Specialty Pharmacy Times, June 2020, Volume 3, Issue 2

This continuing education activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVARTIS PHARMACEUTICALS CORPORATION.

FACULTY

Michael Crowe, PharmD, MBA, CSP, FMPA

Registered Manager of General Operations

Community, A Walgreens Pharmacy

Flint, Michigan

Adjunct Assistant Professor of Clinical Pharmacy

Ferris State University College of Pharmacy

Big Rapids, Michigan

At the completion of this activity, the participant will be able to:

  • Investigate the pathophysiology of psoriatic disease with a focus on the interleukin 17 and interleukin 23 pathways
  • Explore the mechanism of action, safety, efficacy, and role in therapy for current and emerging interleukin 17 and interleukin 23 antagonist biologics for the treatment of psoriasis and/or psoriatic arthritis
  • Determine best practices for specialty pharmacists in the management of psoriatic disease

TARGET AUDIENCE: Specialty pharmacists, specialty pharmacy directors/managers, health-system pharmacists, formulary decision makers, and other pharmacists involved in the care of patients with psoriatic disease

ACTIVITY TYPE:Application

RELEASE DATE: March 16, 2020

EXPIRATION DATE: June 16, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.